The CXXC5 antibody targets the CXXC-type zinc finger protein 5. a nuclear protein containing a conserved CXXC domain that binds unmethylated CpG DNA. CXXC5 plays roles in epigenetic regulation, particularly in DNA methylation and histone modification. It interacts with the Wnt/β-catenin signaling pathway, acting as a feedback inhibitor by promoting β-catenin degradation, thus influencing cell proliferation, differentiation, and apoptosis. Dysregulation of CXXC5 has been linked to cancers (e.g., leukemia, breast cancer), inflammatory diseases, and metabolic disorders, though its role can be context-dependent (tumor-suppressive or oncogenic).
CXXC5 antibodies are critical tools for studying its expression, localization, and interactions in cellular models and tissues. They enable applications like Western blotting, immunohistochemistry, and co-immunoprecipitation to explore its regulatory mechanisms. Recent research also investigates therapeutic potential, such as blocking CXXC5 to reactivate Wnt signaling in tissue regeneration or cancer treatment. However, antibody specificity remains a challenge due to structural similarities among CXXC family proteins. Validated antibodies are essential for distinguishing CXXC5 from homologs like CXXC4 or CXXC1. Ongoing studies aim to refine antibody-based assays and explore CXXC5-targeted therapies, highlighting its dual role in disease pathways and precision medicine.